Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Investing.com - Tvardi Therapeutics Inc (NASDAQ:TVRD) shares plunged 85% on Monday to $6.85, erasing much of its previous 128% six-month gain, following disappointing Phase 2a clinical trial results for its TTI-101 drug in idiopathic pulmonary fibrosis (IPF). The selloff reduced the clinical-stage biotech’s market capitalization to approximately $63 million.
Oppenheimer analyst Jay Olson responded by dramatically cutting the company’s price target to $10.00 from $65.00, while maintaining an Outperform rating on the stock. According to InvestingPro data, analyst targets for TVRD now range from $42 to $78, with a strong buy consensus rating of 1.29.
The clinical trial, known as REVERT-IPF, failed to show TTI-101 separating from placebo on the primary endpoint measuring change from baseline in forced vital capacity (FVC) at week 12, a key measure of lung function.
Oppenheimer noted two specific challenges that complicated data interpretation: lower-than-expected FVC worsening in the placebo group and high discontinuation rates related to gastrointestinal issues among patients receiving the active treatment.
Despite the setback, Oppenheimer expects Tvardi to refocus its approximately $40 million cash balance as of the second quarter of 2025 on developing TTI-101 for hepatocellular carcinoma (HCC), a form of liver cancer. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 4.04, indicating adequate resources for its pipeline development. Get access to 12 additional InvestingPro Tips and comprehensive financial analysis in the Pro Research Report.
In other recent news, Tvardi Therapeutics announced that its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals. The trial, which was randomized, double-blind, and placebo-controlled, involved 88 patients and evaluated TTI-101 both alone and in combination with nintedanib. Despite these results, Barclays initiated coverage on Tvardi Therapeutics with an Overweight rating and set a price target of $61.00. Additionally, Raymond James also began coverage on the company with an Outperform rating and a price target of $62.00. The research firms emphasized Tvardi’s focus on developing small molecule therapeutics for fibrosis-driven diseases. In corporate developments, Tvardi Therapeutics announced that Shaheen Wirk resigned from its board of directors, with the company noting that his departure was not due to any disagreements. Dr. Wirk had been a board member since March 2024, following his role as a special advisor.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.